Search results
BMS Opdivo and Yervoy combo misses primary endpoint in Phase III NSCLC trial
Clinical Trials Arena via Yahoo Finance· 1 hour agoOpdivo is a programmed death-1 (PD-1) immune checkpoint inhibitor. It has been approved to treat a...
New PET agent provides same-day imaging for clear cell renal cell carcinoma patients
Medical Xpress· 6 days agoA novel investigational PET imaging agent can rapidly and accurately visualize lesions in clear cell renal cell cancer (ccRCC) patients according to new research published in the May issue of ...
Iovance (IOVA) Q1 Earnings Surpass, Sales Lag Estimates
Zacks via Yahoo Finance· 3 days agoIovance (IOVA) reports mixed first-quarter results. Shares gain on encouraging initial demand for...
Massive study identifies new biomarkers for renal cancer subtypes, improving diagnosis...
Medical Xpress· 7 days agoThe findings lay the groundwork to identify therapeutic targets in non-clear-cell renal cell carcinomas. Renal < ...
Billionaire Jim Simons Owns These 2 Healthcare Stocks: Should You?
Motley Fool via Yahoo Finance· 18 hours agoExelixis Exelixis specializes in cancer medicines. It earned quite a reputation thanks to its most...
Leads Biolabs is Proud to Announce its Participation in the 2024 ASCO Annual Meeting with One Oral...
Bennington Banner· 8 hours agoThe 2024 American Society of Clinical Oncology (ASCO) Annual Meeting will be held in Chicago from...
Iovance (IOVA) Gears Up for Q1 Earnings: Here's What to Expect
Zacks via Yahoo Finance· 7 days agoInvestors' focus will likely be on Iovance's (IOVA) progress with its ongoing commercial launch for...
Benjamin F. Edwards & Company Inc. Buys Shares of 542 BeiGene, Ltd. (NASDAQ:BGNE)
ETF DAILY NEWS· 5 hours agoBenjamin F. Edwards & Company Inc. purchased a new stake in shares of BeiGene, Ltd. (NASDAQ:BGNE – Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities ...
YOUR HEALTH: Why some kidney cancer patients are living longer
WAFB Baton Rouge· 5 days agoKidney cancer is among the 10 most common cancers in both men and women. A decade ago, advanced...
Wedbush Boosts Janux Therapeutics (NASDAQ:JANX) Price Target to $74.00
ETF DAILY NEWS· 2 days agoJanux Therapeutics (NASDAQ:JANX – Free Report) had its target price increased by Wedbush from $53.00 to $74.00 in a research note published on Wednesday morning, Marketbeat reports. The brokerage ...